​​​
  1. Poor prognosis

Poor prognosis

Price caps on medical devices will be as detrimental for patients as it would be for industry

By: | Published: July 14, 2015 12:38 AM

A price cap on medical devices, which include stents and cardiac implants, is a very bad idea, one that the government should drop right away. Given India imports nearly 75% of its requirement of medical devices, the prices do often become a barrier for patients from the lower income group. But, given the costs of treatment at public healthcare facilities is a fourth of that at private ones, as per data from the National Sample Survey Office (NSSO), it is not as if the choices for low-income patients are very limited. Even if they overwhelmingly choose private sector healthcare—the NSSO data says that more than 70% of Indians indeed prefer this—the government would do better to offer some sort of support to such patients rather than fixing a cap that will unnecessarily punish the device makers as well as the patients, as the latter may have to contend with a shortage of such devices in case the Indian price cap also causes a fall in the availability of the devices, as it did in the case of certain medicines that were brought under price regulation.

The long-term solution would, of course, be to encourage domestic production, and introduce competition that is certain to bring prices down. While the government does in indeed envision a Make in India shift for medical devices, the price caps only serve to deter foreign investors—it is only recently that the segment has been opened up for 100% FDI—and makers, with the latter expected to bring in the know-how. There is the likelihood that it would be years before Indian production—an estimated $3.5 billion industry at the moment—catches up to global quality standards, which would only mean patients’ suffering would be compounded in the interim.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top